Charles Schwab’s Cartesian Therapeutics RNAC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $335K | Buy |
32,168
+7,239
| +29% | +$53.6K | ﹤0.01% | 3314 |
|
|
2026
Q1 | $153K | Sell |
24,929
-371
| -1% | -$2.64K | ﹤0.01% | 3330 |
|
|
2025
Q4 | $182K | Buy |
25,300
+405
| +2% | +$3.27K | ﹤0.01% | 3354 |
|
|
2025
Q3 | $254K | Sell |
24,895
-8
| -0% | -$90 | ﹤0.01% | 3325 |
|
|
2025
Q2 | $259K | Sell |
24,903
-4,400
| -15% | -$46.9K | ﹤0.01% | 3346 |
|
|
2025
Q1 | $386K | Buy |
29,303
+2,500
| +9% | +$44.7K | ﹤0.01% | 3148 |
|
|
2024
Q4 | $480K | Buy |
26,803
+7,755
| +41% | +$157K | ﹤0.01% | 3153 |
|
|
2024
Q3 | $307K | Hold |
19,048
| – | – | ﹤0.01% | 3278 |
|
|
2024
Q2 | $514K | Buy |
19,048
+8,204
| +76% | +$196K | ﹤0.01% | 3187 |
|
|
2024
Q1 | $211K | Hold |
10,844
| – | – | ﹤0.01% | 3231 |
|
|
2023
Q4 | $224K | Hold |
10,844
| – | – | ﹤0.01% | 3263 |
|
|
2023
Q3 | $345K | Hold |
10,844
| – | – | ﹤0.01% | 3193 |
|
|
2023
Q2 | $364K | Buy |
10,844
+8,851
| +444% | +$317K | ﹤0.01% | 3182 |
|
|
2023
Q1 | $83.1K | Hold |
1,993
| – | – | ﹤0.01% | 3278 |
|
|
2022
Q4 | $67.6K | Hold |
1,993
| – | – | ﹤0.01% | 3306 |
|
|
2022
Q3 | $99K | Hold |
1,993
| – | – | ﹤0.01% | 3225 |
|
|
2022
Q2 | $79K | Sell |
1,993
-6,017
| -75% | -$178K | ﹤0.01% | 3311 |
|
|
2022
Q1 | $296K | Buy |
8,010
+353
| +5% | +$22.1K | ﹤0.01% | 3216 |
|
|
2021
Q4 | $749K | Hold |
7,657
| – | – | ﹤0.01% | 3020 |
|
|
2021
Q3 | $956K | Buy |
7,657
+218
| +3% | +$26.3K | ﹤0.01% | 2889 |
|
|
2021
Q2 | $933K | Buy |
7,439
+1,471
| +25% | +$175K | ﹤0.01% | 2956 |
|
|
2021
Q1 | $811K | Sell |
5,968
-457
| -7% | -$56.7K | ﹤0.01% | 2922 |
|
|
2020
Q4 | $585K | Buy |
6,425
+240
| +4% | +$20.8K | ﹤0.01% | 2936 |
|
|
2020
Q3 | $461K | Buy |
6,185
+824
| +15% | +$63.1K | ﹤0.01% | 2892 |
|
|
2020
Q2 | $457K | Buy |
5,361
+4,872
| +996% | +$442K | ﹤0.01% | 2871 |
|
|
2020
Q1 | $36K | Hold |
489
| – | – | ﹤0.01% | 3173 |
|
|
2019
Q4 | $35K | Hold |
489
| – | – | ﹤0.01% | 3143 |
|
|
2019
Q3 | $26K | Sell |
489
-162
| -25% | -$8.61K | ﹤0.01% | 3150 |
|
|
2019
Q2 | $35K | Sell |
651
-2,359
| -78% | -$161K | ﹤0.01% | 3174 |
|
|
2019
Q1 | $215K | Buy |
3,010
+1,887
| +168% | +$120K | ﹤0.01% | 3011 |
|
|
2018
Q4 | $90K | Sell |
1,123
-137
| -11% | -$31.3K | ﹤0.01% | 3097 |
|
|
2018
Q3 | $588K | Buy |
1,260
+137
| +12% | +$55K | ﹤0.01% | 2779 |
|
|
2018
Q2 | $447K | Buy |
1,123
+303
| +37% | +$107K | ﹤0.01% | 2841 |
|
|
2018
Q1 | $251K | Hold |
820
| – | – | ﹤0.01% | 2932 |
|
|
2017
Q4 | $242K | Sell |
820
-167
| -17% | -$73K | ﹤0.01% | 2940 |
|
|
2017
Q3 | $541K | Buy |
987
+330
| +50% | +$176K | ﹤0.01% | 2693 |
|
|
2017
Q2 | $392K | Buy |
+657
| New | +$290K | ﹤0.01% | 2768 |
|
Other funds holding RNAC
6CM
Charles Schwab's RNAC Position: Q2 2026 in Review
Charles Schwab increased its Cartesian Therapeutics (RNAC) stake by 29% in Q2 2026, buying an estimated $53.6K and bringing the position to 32,168 shares worth $335K. The position accounts for ﹤0.01% of the portfolio, ranked #3314.
Charles Schwab first reported a position in RNAC in Q2 2017 and has held it in 37 quarters since. The position peaked at $956K in Q3 2021. 95 funds tracked by Wall St. Rank hold RNAC as of Q2 2026.
- Charles Schwab held 32,168 shares of Cartesian Therapeutics worth $335K as of Q2 2026.
- Charles Schwab bought 7,239 Cartesian Therapeutics shares in Q2 2026, an estimated $53.6K.
- Cartesian Therapeutics made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #3314 holding.
- Charles Schwab first reported a position in Cartesian Therapeutics in Q2 2017 and has held it in 37 quarters since.
- Charles Schwab's Cartesian Therapeutics position peaked at $956K in Q3 2021.
- 95 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q2 2026.
Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.